RATIONALE: (R,S)-ketamine is a rapid and effective antidepressant drug that produces a response in two thirds of patients with treatment-resistant depression (TRD). The underlying biochemical differences between a (R,S)-ketamine responder (KET-R) and non-responder (KET-NR) have not been definitively identified but may involve serine metabolism. OBJECTIVES: The aim of the study was to examine the relationship between baseline plasma concentrations of D-serine and its precursor L-serine and antidepressant response to (R,S)-ketamine in TRD patients. METHODS: Plasma samples were obtained from 21 TRD patients at baseline, 60 min before initiation of the (R,S)-ketamine infusion. Patients were classified as KET-Rs (n = 8) or KET-NRs (n = 13) based upon the difference in Montgomery-Åsberg Depression Rating Scale (MADRS) scores at baseline and 230 min after infusion, with response defined as a ≥50 % decrease in MADRS score. The plasma concentrations of D-serine and L-serine were determined using liquid chromatography-mass spectrometry. RESULTS: Baseline D-serine plasma concentrations were significantly lower in KET-Rs (3.02 ± 0.21 μM) than in KET-NRs (4.68 ± 0.81 μM), p < 0.001. A significant relationship between baseline D-serine plasma concentrations and percent change in MADRS at 230 min was determined using a Pearson correlation, r = 0.77, p < 0.001, with baseline D-serine explaining 60 % of the variance in (R,S)-ketamine response. The baseline concentrations of L-serine (L-Ser) in KET-Rs were also significantly lower than those measured in KET-NRs (66.2 ± 9.6 μM vs 242.9 ± 5.6 μM, respectively; p < 0.0001). CONCLUSIONS: The results demonstrate that the baseline D-serine plasma concentrations were significantly lower in KET-Rs than in KET-NRs and suggest that this variable can be used to predict an antidepressant response following (R,S)-ketamine administration.
RATIONALE: (R,S)-ketamine is a rapid and effective antidepressant drug that produces a response in two thirds of patients with treatment-resistant depression (TRD). The underlying biochemical differences between a (R,S)-ketamine responder (KET-R) and non-responder (KET-NR) have not been definitively identified but may involve serine metabolism. OBJECTIVES: The aim of the study was to examine the relationship between baseline plasma concentrations of D-serine and its precursor L-serine and antidepressant response to (R,S)-ketamine in TRD patients. METHODS: Plasma samples were obtained from 21 TRD patients at baseline, 60 min before initiation of the (R,S)-ketamine infusion. Patients were classified as KET-Rs (n = 8) or KET-NRs (n = 13) based upon the difference in Montgomery-Åsberg Depression Rating Scale (MADRS) scores at baseline and 230 min after infusion, with response defined as a ≥50 % decrease in MADRS score. The plasma concentrations of D-serine and L-serine were determined using liquid chromatography-mass spectrometry. RESULTS: Baseline D-serine plasma concentrations were significantly lower in KET-Rs (3.02 ± 0.21 μM) than in KET-NRs (4.68 ± 0.81 μM), p < 0.001. A significant relationship between baseline D-serine plasma concentrations and percent change in MADRS at 230 min was determined using a Pearson correlation, r = 0.77, p < 0.001, with baseline D-serine explaining 60 % of the variance in (R,S)-ketamine response. The baseline concentrations of L-serine (L-Ser) in KET-Rs were also significantly lower than those measured in KET-NRs (66.2 ± 9.6 μM vs 242.9 ± 5.6 μM, respectively; p < 0.0001). CONCLUSIONS: The results demonstrate that the baseline D-serine plasma concentrations were significantly lower in KET-Rs than in KET-NRs and suggest that this variable can be used to predict an antidepressant response following (R,S)-ketamine administration.
Authors: Christian Henneberger; Lucie Bard; Claire King; Alistair Jennings; Dmitri A Rusakov Journal: Neurochem Res Date: 2013-02-07 Impact factor: 3.996
Authors: Mark J Niciu; David A Luckenbaugh; Dawn F Ionescu; Sara Guevara; Rodrigo Machado-Vieira; Erica M Richards; Nancy E Brutsche; Neal M Nolan; Carlos A Zarate Journal: J Clin Psychiatry Date: 2014-05 Impact factor: 4.384
Authors: Jana Jirásková-Vaníčková; Rudiger Ettrich; Barbora Vorlová; Hillary E Hoffman; Martin Lepšík; Petr Jansa; Jan Konvalinka Journal: Curr Drug Targets Date: 2011-06 Impact factor: 3.465
Authors: Y Ji; S Hebbring; H Zhu; G D Jenkins; J Biernacka; K Snyder; M Drews; O Fiehn; Z Zeng; D Schaid; D A Mrazek; R Kaddurah-Daouk; R M Weinshilboum Journal: Clin Pharmacol Ther Date: 2010-11-24 Impact factor: 6.875
Authors: E Pomarol-Clotet; G D Honey; G K Murray; P R Corlett; A R Absalom; M Lee; P J McKenna; E T Bullmore; P C Fletcher Journal: Br J Psychiatry Date: 2006-08 Impact factor: 9.319
Authors: Guillermo M Alexander; Erin Reichenberger; B Lee Peterlin; Marielle J Perreault; John R Grothusen; Robert J Schwartzman Journal: Pain Res Treat Date: 2013-11-04
Authors: Panos Zanos; Ruin Moaddel; Patrick J Morris; Lace M Riggs; Jaclyn N Highland; Polymnia Georgiou; Edna F R Pereira; Edson X Albuquerque; Craig J Thomas; Carlos A Zarate; Todd D Gould Journal: Pharmacol Rev Date: 2018-07 Impact factor: 25.468
Authors: Nagendra S Singh; Michel Bernier; Simonetta Camandola; Mohammed A Khadeer; Ruin Moaddel; Mark P Mattson; Irving W Wainer Journal: Br J Pharmacol Date: 2015-07-31 Impact factor: 8.739